Alamar Biosciences (NASDAQ:ALMR) Major Shareholder Corporate Gp Vi Ltd. Qiming Sells 133,811 Shares of Company Stock

Alamar Biosciences, Inc. (NASDAQ:ALMR) major shareholder Corporate Gp Vi Ltd. Qiming sold 133,811 shares of the firm’s stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $29.33, for a total transaction of $3,924,676.63. Following the sale, the insider owned 172,338 shares in the company, valued at approximately $5,054,673.54. The trade was a 43.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

• On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.31, for a total transaction of $6,329,182.65.
• On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
• On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The shares were sold at an average price of $26.34, for a total value of $1,988,880.72.
• On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.02, for a total value of $3,674.72.
• On Thursday, October 15th, Corporate Gp Vi Ltd. Qiming sold 173,537 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.73, for a total value of $4,812,181.01.

Alamar Biosciences Stock Up 3.3%

Shares of NASDAQ:ALMR traded up $0.97 during mid-day trading on Friday, reaching $30.69. 748,124 shares of the stock were exchanged, compared to its average volume of 772,442. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $2.13 billion and a P/E ratio of -15.66. Alamar Biosciences, Inc. has a one year low of $18.84 and a one year high of $39.61. The business’s 50 day moving average price is $30.74.

Alamar Biosciences (NASDAQ:ALMR) last released its earnings results on Tuesday, August 11th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.14. The firm had revenue of $29.43 million during the quarter. Analysts anticipate that Alamar Biosciences, Inc. will post -1.22 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ALMR. Weiss Ratings upgraded shares of Alamar Biosciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, October 8th. Stifel Nicolaus increased their target price on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. lifted their price target on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Finally, TD Cowen reiterated a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Alamar Biosciences presently has an average rating of “Moderate Buy” and an average target price of $31.80.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ALMR. State Street Corp bought a new position in Alamar Biosciences in the second quarter valued at approximately $3,930,000. Squarepoint Ops LLC bought a new stake in shares of Alamar Biosciences during the 2nd quarter worth approximately $283,000. Braidwell LP bought a new stake in shares of Alamar Biosciences during the 2nd quarter worth approximately $29,365,000. Finally, Wellington Management Group LLP bought a new stake in shares of Alamar Biosciences during the 2nd quarter worth approximately $12,407,000.

Alamar Biosciences Company Profile

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.